Literature DB >> 21411360

Ligand specificity, privileged substructures and protein druggability from fragment-based screening.

Sarah Barelier1, Isabelle Krimm.   

Abstract

Fragment-based screening has now become an established method for the generation of lead molecules against therapeutic targets. Fragment molecules are simple, low molecular-weight compounds with few chemical functionalities. These characteristics lead to high hit rates for fragment screening as compared to the more classical High-Throughput Screening of drug-like molecules and raise the question of the specificity of fragment molecules. This review analyzes recent outcomes of fragment screenings published in the literature, showing that the specificity of the fragments can be related to their structures and physico-chemical properties. We also discuss both the concept of privileged fragment scaffolds and the role of fragment-based screening in predicting protein druggability, highlighted by recent publications in the field.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21411360     DOI: 10.1016/j.cbpa.2011.02.020

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  13 in total

Review 1.  Genetic Approaches to Facilitate Antibacterial Drug Development.

Authors:  Dirk Schnappinger
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-13       Impact factor: 6.915

2.  Inhibition of noroviruses by piperazine derivatives.

Authors:  Dengfeng Dou; Guijia He; Sivakoteswara Rao Mandadapu; Sridhar Aravapalli; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2011-11-15       Impact factor: 2.823

3.  Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Lili Chu; Yusong Zhang; Kristin Terry; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2013-01-26       Impact factor: 6.514

4.  Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules.

Authors:  Yirui Guo; Carrie L Partch; Jason Key; Paul B Card; Victor Pashkov; Anjana Patel; Richard K Bruick; Heiko Wurdak; Kevin H Gardner
Journal:  ACS Chem Biol       Date:  2012-12-26       Impact factor: 5.100

5.  New Frontiers in Druggability.

Authors:  Dima Kozakov; David R Hall; Raeanne L Napoleon; Christine Yueh; Adrian Whitty; Sandor Vajda
Journal:  J Med Chem       Date:  2015-08-11       Impact factor: 7.446

6.  High-throughput screening of small molecule ligands targeted to live bacteria surface.

Authors:  Jeong Heon Lee; Sunny Park; Hoon Hyun; Mark W Bordo; Rafiou Oketokoun; Khaled A Nasr; John V Frangioni; Hak Soo Choi
Journal:  Anal Chem       Date:  2013-03-18       Impact factor: 6.986

7.  A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline.

Authors:  Xin Chen; Shanshan Qin; Shuai Chen; Jinlong Li; Lixin Li; Zhongling Wang; Quan Wang; Jianping Lin; Cheng Yang; Wenqing Shui
Journal:  Sci Rep       Date:  2015-02-10       Impact factor: 4.379

8.  Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger.

Authors:  Thomas C R Miller; Trevor J Rutherford; Kristian Birchall; Jasveen Chugh; Marc Fiedler; Mariann Bienz
Journal:  ACS Chem Biol       Date:  2014-10-24       Impact factor: 4.634

9.  Virtual and biophysical screening targeting the γ-tubulin complex--a new target for the inhibition of microtubule nucleation.

Authors:  Olivier Cala; Marie-Hélène Remy; Valérie Guillet; Andreas Merdes; Lionel Mourey; Alain Milon; Georges Czaplicki
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

10.  Increasing chemical space coverage by combining empirical and computational fragment screens.

Authors:  Sarah Barelier; Oliv Eidam; Inbar Fish; Johan Hollander; Francis Figaroa; Ruta Nachane; John J Irwin; Brian K Shoichet; Gregg Siegal
Journal:  ACS Chem Biol       Date:  2014-05-20       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.